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Small is beautiful: virus- like 
particles as vaccines
Virus- like particles (VLPs) are nanoscale structures that are mimics of virus particles themselves. 
They are stripped of any infection risk but can perform like viruses in some tasks although they are 
unable to spread. They are inherently safe and may offer additional advantages when compared to 
the viruses from which they derive. If they are produced by a recombinant route, as is very common, 
they can be modified by alteration of the sequences used to add functionality their parental versions 
did not possess, such as staying in a particular conformation, carrying different cargoes or targeting 
specific cells. It is probably true that VLPs are ascribed more promise than may ever be realized but 
their positive attributes are very real, they have already appeared as successful products and their 
potential is certainly far from exhausted.
Ian Jones (University of 
Reading, UK)
Polly Roy (London 
School of Hygiene and 
Tropical Medicine, UK)
Vaccine Strategies
The term “virus- like particle” (VLP) is, perhaps too 
liberally, applied to many small aggregates whether they 
derive from viruses or not. To a degree this is justified 
as, indeed, viruses are generally small (most are ~50–150 
nm diameter) with regular dimensions, so anything that 
resembles such structures may have the term applied 
to it. In recent years the VLP field has overlapped the 
emerging field of nanotechnology, which is a term 
applied to anything dependent on structures of ~100 nm 
diameter or less. The latter includes a range of structures 
with various intended functions, among them stimula-
tion of the immune system, drug delivery, the encapsida-
tion of nucleic acids or use as building blocks for larger 
arrays.
Although VLPs today generally mean a recombinant 
product made following the expression of a discrete 
number of virus- encoded proteins, it is important to 
note that VLPs are natural components of many virus 
replication cycles. The default infection for most viruses 
is acute. That is to say, a virus enters a cell and programs 
it to produce more virus particles. Speed and abundance 
are of essence as the virus has only a limited time before 
the immune system engages and starts to shut the 
infection down. Many viruses complete their replication 
cycle within a few hours, typically producing hundreds 
or thousands of new particles. So much virus protein 
is produced, notably the virus structural proteins that 
assemble virus particles, in such a short period of time 
that errors are inevitable. Coupled with this, as virus 
genomes are genetically limited, most virus particle 
assembly is self- directed by the structural proteins 
concerned. Hence incomplete or empty virus particles 
can partly form or form without anything inside them 
(Figure 1).
In a natural infection, aberrant particles are wasteful 
but tolerated as long as sufficient authentic virus is 
produced for onward transmission. Such particles, 
variously referred to as empty particles or defective 
interfering (DI) particles, qualify as VLPs and they 
occur in many virus types. Hepatitis B virus, for 
example, one of the smallest viruses, made of only two 
proteins, core and surface, produces both empty cores 
and aggregates of the surface protein during productive 
infection. Picornaviruses, a huge family of small RNA 
viruses that assemble from three structural proteins, 
also produce non- infectious empty capsids during their 
replication cycle (Figure 1). What these natural examples 
demonstrate is that VLP formation is inherent and not 
dependent on any complex cellular pathway. It follows 
that if the same proteins are produced in abundance by 
genetic means then VLPs assembly will similarly occur. 
Moreover, unless modification of the structural protein 
sequence occurs at a point which abrogates the ability 
to self- assemble then the same proteins with extended 
or swapped sequences will continue to form VLPs. No 
longer just mimics of the viruses from whose sequence 
they derive, such structures can act as scaffolds for the 
presentation of other polypeptides. Viruses generally 
demonstrate tropism, the particular property of binding 
one or other cell type as a result of the specific interaction 
with a virus receptor. VLPs that assemble to include the 
basis of tropism, the receptor binding protein, retain 
this ability and will also target specific cell types. In 
the normal virus the payload for delivery is the virus 
genome but if VLPs are assembled in its absence then 
the corresponding space can be filled with a cargo which 
is then delivered intact to particular cells by virtue of the 
natural tropism associated with the virus from which the 
VLPs were derived (Figure 2). The ability to form VLPs 
and their manipulation therefore offers a technology 
to safely mimic viruses themselves, to render non- 
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Figure 1. Virus- like particles are not new and occur as a side product in many virus replication cycles. (a) In the late stage of 
virus replication, the synthesis of the virus structural proteins is so prolific they make errors that result in empty particles. (b 
and c) Examples of empty particle assembly during the normal replication cycles of picornaviruses (b) and the more complex 
orbiviruses (c). F, full; E, empty; P, part assembled.
Figure 2. Types of virus- like particles. Top: all VLPs begin with the high- level synthesis of a protein, usually virus structural 
proteins, able to self- assemble. Assembly proceeds but in the absence of any other virus component, notably the genome, 
leading to the formation of a regular but empty VLP. Middle: if a sequence is inserted in the external face of the assembly 
protein and assembly is not compromised, a decorated VLP is the result. The same can be achieved by addition after VLP 
synthesis (top right). Bottom: a similar fusion but designed for the inside of the VLP can result in ligand capture and a loaded 







K user on 06 August 2021
3 August 2021 © The Authors. Published by Portland Press Limited under the Creative Commons Attribution License 4.0 (CC BY- NC- ND)
Vaccine Strategies
offer protection and targeting to molecules that would 
otherwise be susceptible to degradation or dispersal. 
This utility is in marked contrast to the pathology that 
is the preoccupation of studies on the authentic virus.
Of all the potential uses for VLPs the most obvious 
and widespread is their use as vaccines. As noted, VLP 
assembly invariably involves the structural proteins of the 
virus particle, the same proteins that stimulate immunity 
during natural infection. In consequence, a VLP can act 
to stimulate the same immunity as that engendered by 
infection. The ability to produce VLPs by the expression 
of select viral proteins means there is no risk during 
manufacture, even for viruses that would otherwise 
require high containment. Manufacture may still be 
difficult or expensive but the VLP approach removes 
an infection risk that would be otherwise severely 
limiting. There are other reasons too for why VLPs 
are advantageous, as the structure of the VLP, with its 
repeating copies of one or a few virus proteins, stimulates 
immunity to a greater extent than the same material in 
disassembled form. An early step in the generation of 
immunity is the engagement of any pathogen by the 
B- cell, which carries on its surface a low affinity but 
very broadly reactive receptor (the BCR). The “match” 
between the foreign protein and the BCR triggers internal 
signalling that marks the beginning of the true immune 
response and this interaction is much more potent if 
multiple rather than single BCRs are engaged. A VLP 
naturally causes clustering of the BCR that single copies 
of the same proteins could not (Figure 3). A further step, 
internalization and degradation of foreign proteins for 
presentation to the awakening immune cells, is also 
enhanced as a VLP clearly delivers far more material 
than would a single copy of each of its constituent parts. 
These processes mean that VLPs represent not only a safe 
and manufacturable form of a vaccine but, on a weight 
for weight basis with individual virus proteins, a vaccine 
that is more able to generate the immunity associated 
with protection.
This concept is ably demonstrated by reference to 
some of the successful VLP vaccines now in use. The first 
of these (HBV), for hepatitis B, is a slight cheat. The basis 
of HBV protection is immunity to the surface antigen (S) 
and this protein was an early exemplar of the expression 
of viral proteins in recombinant expression systems. The 
universality of the genetic code means that the sequence 
of HBV S, when appended to the correct genetic control 
elements, produces the S protein in simple, easy to grow 
organisms like yeast, from which it can be purified by 
standard biochemistry. Fortuitously, purified S protein 
assembles into small aggregates that resemble VLPs 
even though the basis of the virus particle, the core 
protein, is not present. This assembled material is a 
very good vaccine and has been used worldwide since 
the mid- 1980s. The HBV core meanwhile has been used 
widely as a scaffold for the development of many other 
vaccines, candidates for malaria and HIV among them. 
Initial work required the formation of a fusion protein in 
which the sequence of interest, the target for immunity, 
was genetically coupled to the HBV core protein 
resulting in a single polypeptide which assembles into 
a VLP. This is not always successful, however, as the 
sequence introduced sometimes folds on translation 
into a structure that prevents the HBV core from self- 
assembling. More recently, novel coupling technologies 
have been applied so that cargoes can be conjugated to 
the VLP after synthesis, which should result in a greater 
range of possibilities.
A second well- known example of a successful VLP- 
based vaccine has been the vaccine against human 
papillomavirus, the virus associated with cervical and 
other cancers. In this case, although the virus itself uses 
two proteins to form the particle, L1 and L2, L1 alone 
is sufficient to form a VLP. The ability to form a VLP 
revolutionized the vaccine possibilities for HPV as the 
virus itself cannot be grown in bulk, a case of the VLP 
providing not only a structural mimic but also a means 
to an end that had, hitherto, not been attainable. The 
expression technology in this case is either yeast or insect 
cells, both suitable for large- scale manufacture, and 
current vaccines are a mixture of up to nine serotypes 
providing protection against most circulating viruses of 
concern. Less well known but equally successful in the 
animal vaccine market is a vaccine for porcine circovirus 
type 2 (PCV2) which uses a VLP consisting of a single 
virus protein. Many other VLP- based vaccines are also 
in development.
Although VLPs have been successfully deployed 
as vaccines it would be wrong to conclude that they 
Figure 3. Pathways by which VLPs stimulate immunity. The multivalent nature of the VLP can 
cross- link the B- cell receptor on binding leading to clustering of the tails and strong signal 
transduction to activate the cell. Single subunit binding cannot do the same as cross- linking 
is not possible. On entry into antigen- presenting cells the mass of the VLP and its potential to 







K user on 06 August 2021
4  August 2021 © The Authors. Published by Portland Press Limited under the Creative Commons Attribution License 4.0 (CC BY- NC- ND)
Vaccine Strategies
are without issues. The immune stimulation that their 
polyvalent nature affords still does not mimic the 
immune triggering induced by the natural infection in 
some cases, and several boosts, or the inclusion of an 
adjuvant, may be needed to generate full protection. 
Similarly, manufacturing costs are not trivial as yields 
are variable and the purification extensive. VLPs can 
also exhibit instability with a tendency to disassemble 
on storage, meaning that cold chains may be required 
for their deployment. It is noteworthy in relation to the 
pandemic that VLP vaccines have not been among the 
front runners for a protective vaccine, despite the fact that 
coronavirus VLPs are readily formed from only two or 
three structural proteins. A balanced view would be that 
VLPs occupy a now well- established position within a 
range of vaccine technologies and their use will continue 
to grow. However, the choice of whether to make a VLP 
or not will depend on the particular vaccine required.■
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